Publication date: Oct 01, 2019
Sandy, S. and Richard, A. Is Huntington’s disease on the threshold of a new era in treatment? 06709. 2019 Neurodegener Dis Manag (9):5.
|Boston Red Sox||Huntington, West Virginia|
|British record labels||Antisense therapy|
|Branches of biology|
- Antisense oligonucleotides might change the therapeutic landscape for Huntington’s disease.
- Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
- Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide.
- Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound.